Drug Profile
Research programme: drug discovery - BioFocus DPI/Ono Pharmaceuticals
Latest Information Update: 15 Apr 2014
Price :
$50
*
At a glance
- Originator BioFocus DPI; Ono Pharmaceutical
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 18 Apr 2007 Preclinical trials in Undefined indication in Europe (unspecified route)